At The Uromigos Live & Unplugged event, Stephanie Berg, DO, Dana-Farber Cancer Institute, describes her presentation given on second-line treatment for mUC during the Rising Stars panel.
If enfortumab vedotin plus pembrolizumab becomes the first-line standard of care for mUC, is platinum-based chemotherapy followed by immunotherapy maintenance the next course of action?
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.